Experts recommended by China Pharmaceutical Association to participate in IFPMA ICH E17 implementation working group

Source: China pharmaceutical innovation promotion association may 17, 2018 in December 2016, China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") formally joined the International Federation of Pharmaceutical Manufacturers & Associations (hereinafter referred to as "IFPMA") and became the only member of the association representing Chinese local pharmaceutical enterprises As a permanent observer of the International Coordinating Council for technical requirements of human drugs (ICH) and the ICH Secretariat, IFPMA was discussed and adopted at the ICH conference in June 2017 As an association representing the global biomedical industry, IFPMA is qualified to recommend experts to participate in the ICH guiding principles expert working group Previously, the ICH management committee approved IFPMA to establish an ICH E17 international multi center clinical trial (MRCT) executive expert working group to promote the implementation of E17 guiding principles, improve the global research and development environment, accelerate the synchronous research and development of new drugs, improve the efficiency and ability of global drug research and development, and reasonably allocate resources, Reduce the waste of resources in the process of drug development, solve the problems faced in promoting the implementation of guiding principles, so as to better help regulators make decisions Through internal screening, China pharmaceutical promotion association nominated two experts to participate in the E17 implementation working group to IFPMA At present, the response from IFPMA has been received All the two experts nominated by China pharmaceutical promotion association have passed the review and become members of the E17 implementation working group Wu Yilong, vice chairman of the pharmaceutical clinical research professional committee of the China Association for the promotion of drugs and vice president of Guangdong People's Hospital, was selected as the leader of the E17 executive working group, leading the working group to carry out relevant work; Ma Zheng, chief data scientist of Gemini biomedical technology (Shanghai) Co., Ltd., was selected as the expert of the E17 executive working group China Council for the promotion of drugs recommends experts from the domestic pharmaceutical industry to be selected as the leader of IFPMA E17 implementation working group, which will help China more directly participate in the implementation of E17 guiding principles, Learn from the advanced experience of other countries and regions in carrying out multi center clinical trials, provide a platform for communication and exchange between Chinese and international experts in related fields, improve the ability of Chinese clinical research and innovative drug research and development, and promote the smooth transformation and implementation of E17 guiding principles in China.